CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 142 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.69 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $31,177 | +135.1% | 2,091 | +72.7% | 0.00% | – |
| Q2 2023 | $13,260 | +132500.0% | 1,211 | +5.3% | 0.00% | – |
| Q1 2023 | $10 | +42.9% | 1,150 | 0.0% | 0.00% | – |
| Q4 2022 | $7 | -99.8% | 1,150 | 0.0% | 0.00% | – |
| Q3 2022 | $4,000 | +33.3% | 1,150 | 0.0% | 0.00% | – |
| Q2 2022 | $3,000 | -82.4% | 1,150 | -79.0% | 0.00% | – |
| Q1 2022 | $17,000 | -45.2% | 5,470 | -47.8% | 0.00% | – |
| Q4 2021 | $31,000 | +675.0% | 10,470 | +810.4% | 0.00% | – |
| Q3 2021 | $4,000 | -20.0% | 1,150 | 0.0% | 0.00% | – |
| Q2 2021 | $5,000 | 0.0% | 1,150 | 0.0% | 0.00% | – |
| Q1 2021 | $5,000 | -66.7% | 1,150 | -56.6% | 0.00% | – |
| Q4 2020 | $15,000 | +50.0% | 2,650 | +89.3% | 0.00% | – |
| Q3 2020 | $10,000 | +100.0% | 1,400 | 0.0% | 0.00% | – |
| Q2 2020 | $5,000 | +25.0% | 1,400 | -25.5% | 0.00% | – |
| Q4 2019 | $4,000 | -20.0% | 1,880 | +102.2% | 0.00% | – |
| Q3 2019 | $5,000 | +66.7% | 930 | +116.3% | 0.00% | – |
| Q2 2019 | $3,000 | -50.0% | 430 | 0.0% | 0.00% | – |
| Q1 2019 | $6,000 | +100.0% | 430 | 0.0% | 0.00% | – |
| Q4 2018 | $3,000 | -40.0% | 430 | 0.0% | 0.00% | – |
| Q3 2018 | $5,000 | – | 430 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
| Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
| Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
| Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
| Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
| Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
| Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
| MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |